The development of dendritic cell vaccine-based immunotherapies for glioblastoma

David A Reardon; Duane A Mitchell

doi:10.1007/s00281-016-0616-7

The development of dendritic cell vaccine-based immunotherapies for glioblastoma

Semin Immunopathol. 2017 Feb;39(2):225-239. doi: 10.1007/s00281-016-0616-7. Epub 2017 Jan 30.

Authors

David A Reardon¹, Duane A Mitchell²

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Dana 2134, Boston, MA, 02215-5450, USA. David_Reardon@dfci.harvard.edu.
² Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, 32605, USA.

PMID: 28138787
DOI: 10.1007/s00281-016-0616-7

Abstract

In this review, we focus on the biologic advantages of dendritic cell-based vaccinations as a therapeutic strategy for cancer as well as preclinical and emerging clinical data associated with such approaches for glioblastoma patients.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antigen-Presenting Cells / immunology
Antigen-Presenting Cells / metabolism
Antigens, Neoplasm / immunology
Cancer Vaccines / administration & dosage
Cancer Vaccines / adverse effects
Cancer Vaccines / immunology*
Cancer Vaccines / therapeutic use*
Cell Movement / immunology
Clinical Trials as Topic
Dendritic Cells / immunology*
Dendritic Cells / metabolism
Disease Models, Animal
Glioblastoma / immunology*
Glioblastoma / therapy*
Humans
Immunotherapy* / adverse effects
Immunotherapy* / methods
Vaccination

Substances

Antigens, Neoplasm
Cancer Vaccines